Filing Details
- Accession Number:
- 0001104659-25-032062
- Form Type:
- 13D Filing
- Publication Date:
- 2025-04-03 20:00:00
- Filed By:
- Charles Cherington
- Company:
- Eterna Therapeutics Inc. (NYSEMKT:ERNA)
- Filing Date:
- 2025-04-04
- SEC Url:
- 13D Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Charles Cherington | 20,432,634 | 0 | 20,432,634 | 0 | 20,432,634 | 32.8% |
Filing
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 6)
|
Ernexa Therapeutics Inc. (Name of Issuer) |
Common Stock, par value $0.005 per share (Title of Class of Securities) |
114082209 (CUSIP Number) |
Charles Cherington c/o Ara Partners, LLC,, 200 Berkeley Street, 26th Floor Boston, MA, 02116 (617) 838-3053 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
04/02/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 114082209 |
| 1 |
Name of reporting person
Charles Cherington | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
PF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
20,432,634.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
32.8 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
Rows 7, 9 and 11 consist of (i) 20,401,602 shares of common stock, par value $0.005 per share (the "Common Stock"), of Ernexa Therapeutics Inc. (the "Issuer") and (ii) 31,032 shares of Common Stock issuable upon conversion of 71,306 shares of Series A convertible preferred stock of the Issuer (assuming a conversion rate of 2.2978).
Row 13 is calculated based on an aggregate of 62,209,977 shares of Common Stock of the Issuer outstanding, which is calculated by adding (i) 52,244,929 shares of Common Stock of the Issuer outstanding as of March 10, 2025 as reported on the Issuer's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 12, 2025, (ii) 9,934,016 shares of Common Stock of the Issuer sold in the First Closing of the Private Placement (each as defined below) as reported on the Issuer's Current Report on Form 8-K filed with the SEC on April 3, 2025 and (iii) 31,032 shares of Common Stock issuable upon conversion of 71,306 shares of Series A convertible preferred stock within 60 days, which are deemed outstanding pursuant to Rule 13-3(d)(1)(i).
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock, par value $0.005 per share | |
| (b) | Name of Issuer:
Ernexa Therapeutics Inc. | |
| (c) | Address of Issuer's Principal Executive Offices:
1035 Cambridge Street, Suite 18A, Cambridge,
MASSACHUSETTS
, 02141. | |
Item 1 Comment:
Pursuant to Rule 13d-2 promulgated under the Securities Exchange Act of 1934, as amended, this Amendment No. 6 to Schedule 13D (this "Amendment No. 6") amends certain Items of the Schedule 13D originally filed with the SEC on May 13, 2021 (the "Original Schedule 13D"), as amended by Amendment No. 1 thereto filed with the SEC on March 16, 2022 ("Amendment No. 1"), Amendment No. 2 thereto filed with the SEC on December 14, 2022 ("Amendment No. 2"), Amendment No. 3 thereto filed with the SEC on September 7, 2023 ("Amendment No. 3"), Amendment No. 4 thereto filed with the SEC on December 20, 2023 (Amendment No. 4) and Amendment No. 5 thereto filed with the SEC on March 5, 2025 ("Amendment No. 5," and the Original Schedule 13D, as amended by Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5 and this Amendment No. 6 are collectively referred to herein as the "Schedule 13D") by furnishing the information set forth below. Except as set forth below, all previous Items are unchanged. | ||
| Item 3. | Source and Amount of Funds or Other Consideration | |
The information provided in Item 5 of this Amendment No. 6 is incorporated by reference to this Item 3. | ||
| Item 4. | Purpose of Transaction | |
Item 4 is hereby amended by adding the following: The Reporting Person acquired 3,768,397 shares of common stock of the Issuer pursuant to the Purchase Agreement in the First Closing (each as defined below) and, if the Issuer's stockholders approve the Private Placement, will receive an additional 21,241,163 shares of the Issuer's common stock in the Second Closing (as defined below). Other than the shares that may be acquired in the Second Closing, the Reporting Person has no present plan or proposal that relates to, or could result in, any of the events referred to in paragraphs (a) through (j) inclusive, of Item 4 of Schedule 13D. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | As of April 2, 2025, the Reporting Person owned directly (i) 20,401,602 shares of Common Stock of the Issuer and (ii) 31,032 shares of Common Stock issuable upon conversion of 71,306 shares of Series A convertible preferred stock of the Issuer (assuming a conversion rate of 2.2978). Rows 11 and 13 set forth on the cover page to this Amendment No. 6 are hereby incorporated by reference in this Item 5 (a). | |
| (b) | Rows 7 through 10, inclusive, set forth on the cover page to this Amendment No. 6 are hereby incorporated by reference in this Item 5(b). | |
| (c) | On April 2, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person, pursuant to which the Issuer agreed to issue and sell to such accredited investors in a private placement an aggregate of approximately 58,262,918 shares of the Issuer's common stock (or pre-funded warrants to purchase shares of the Issuer's common stock), at a purchase price of $0.1046 per share, for an aggregate purchase price of approximately $7,250,000 (the "Private Placement"). For purposes of complying with Listing Rules 5635(b) and 5635(d) of the Nasdaq Stock Market LLC, the Private Placement will take place in two separate closings. The first closing took place on April 2, 2025 (the "First Closing") in which the Company sold (i) an aggregate amount of 9,934,016 shares of the Issuer's common stock and (ii) pre-funded warrants to purchase up to an aggregate amount of 509,736 shares of the Issuer's common stock. The second closing (the "Second Closing") will include the sale and issuance of an additional 48,328,902 shares of the Issuer's common stock and pre-funded warrants to purchase up to 10,539,000 shares of the Issuer's common stock. The Second Closing is conditioned upon, among other customary closing conditions, the receipt of stockholder approval of the Private Placement. The Issuer has agreed to hold a meeting of its stockholders for the purpose of obtaining stockholder approval of the Private Placement as soon as reasonably possible following the mailing of a proxy statement, but not later than the later of (i) June 30, 2025 or (ii) if the Securities and Exchange Commission (the "SEC") notifies the Company that it will review the preliminary proxy statement, July 30, 2025. If the stockholders do not approve the Private Placement, the Second Closing will not take place. Each of the purchasers party to the Purchase Agreement has agreed to vote all shares of voting capital stock of the Issuer owned by such purchaser (other than shares acquired at the First Closing) in favor of the approval of the Private Placement.
The Issuer agreed to file a registration statement for the resale of the shares issued, and the shares underlying the pre-funded warrants issued in the First Closing within 15 days of the First Closing, and to file an additional registration statement within 10 days after the Second Closing, for the resale of the shares issued and the shares underlying the pre-funded warrants issued in the Second Closing. The Issuer also agreed to use its reasonable best efforts to have the initial registration statement declared effective within 45 days from the filing date (or 60 days if the registration statement is reviewed by the SEC) and to have the additional registration statement declared effective within 30 days of the filing date (or 60 days if the registration statement is reviewed by the SEC).
Pursuant to the Purchase Agreement, the Reporting Person acquired 3,768,397 shares of the Issuer's Common Stock in the First Closing. If the Issuer's stockholders approve the Private Placement, the Reporting Person is expected to receive 21,241,163 shares of the Issuer's common stock in the Second Closing. | |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer | |
Pursuant to the Purchase Agreement, the Reporting Person has agreed, along with all other purchasers party to the Purchase Agreement, to vote all shares of voting capital stock of the Issuer owned by the Reporting Person (other than shares acquired in the First Closing) in favor of the approval of the Private Placement at any meeting of the Issuer's stockholders where such approval is sought. If the Reporting Person fails to vote the shares pursuant to the Purchase Agreement, the Reporting Person agrees to appoint the Chief Executive Officer of the Issuer to act as the proxy for the Reporting Person's shares that are permitted to vote at any such stockholder meeting. | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|